Clinical trial NCT04824092: Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
Official title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Diffuse Large B-cell Lymphoma
Keywords: DLBCL
CD19
monoclonal antibody
tafasitamab
lenalidomide
R-CHOP
Diffuse Large B-cell Lymphoma
Lead sponsor: Incyte Corporation
Sponsor class: INDUSTRY
First posted: 2021-04-01
Enrollment: 899
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL


Eligibility criteria: Major Inclusion Criteria:

* Previously untreated patients with local biopsy-proven, CD20-positive DLBCL, including one of the following diagnoses by 2016 World Health Organization (WHO) classification of lymphoid neoplasms are eligible:

  1. DLBCL, NOS including GCB type, ABC type
  2. T-cell rich large BCL
  3. Epstein-Barr virus-positive DLBCL, NOS
  4. Anaplastic lymphoma kinase (ALK)-positive large BCL
  5. Human herpes virus-8 (HHV8)-positive DLBCL, NOS
  6. High-grade BCL with MYC and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements (double-hit or triple-hit lymphoma). Please note: Patients must be appropriate candidates for R-CHOP. If an investigator deems a patient with a known double- or triple-hit lymphoma (HGBL) should be treated more aggressively (e.g. dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab \[DA-EPOCH-R\] or cyclophosphamide, vincristine, doxorubicin and dexamethasone (CVAD) followed by methotrexate and cytarabine \[Hyper CVAD\]), this patient would not be considered eligible for this study
  7. HGBL-NOS
  8. DLBCL coexistent with either follicular lymphoma (FL) of any grade, gastric MALT lymphoma or non-gastric MALT lymphoma
  9. FL grade 3b
* Availability of archival or freshly collected tumor tissue sent for retrospective central pathology review
* IPI status of 3 to 5 (for patients \> 60 years of age) or aaIPI 2 to 3 (for patients ≤ 60 years of age)
* Diagnosis to treatment interval, defined as the time between the date of DLBCL diagnosis (date of the first biopsy specimen containing B Cell lymphoma according to the local pathology report) and the start of treatment (C1D1) ≤ 28 days
* ECOG performance status of 0, 1, or 2
* Left ventricular ejection fraction equal to or greater 50% as assessed by local echocardiography or cardiac multi-gated acquisition (MUGA) scan
* Adequate hematologic function
* Female participants: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and refrain from breast feeding and donating eggs; agreement to ongoing pregnancy testing during the course of the study, and after study therapy has ended
* Male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom and agreement to refrain from donating sperm

Major Exclusion Criteria:

* Any other histological type of lymphoma according to WHO 2016 classification of lymphoid neoplasms, e.g., primary mediastinal (thymic) large B-cell lymphoma, Burkitt's lymphoma, BCL, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma (grey-zone lymphoma); primary effusion lymphoma; primary cutaneous DLBCL, leg type; primary DLBCL of the CNS; DLBCL arising from CLL or indolent lymphoma
* History of prior non-hematologic malignancy except for the following:

  1. Malignancy treated with curative intent and with no evidence of active disease present for more than 2 years before screening
  2. Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled non-melanomatous skin cancer
  3. Adequately treated carcinoma in situ without current evidence of disease
* Any systemic anti-lymphoma and/or investigational therapy prior to the start of C1D1, except for permitted pre-phase treatment
* Contraindication to any of the individual components of R-CHOP, including prior receipt of anthracyclines
* Known CNS lymphoma involvement
* Known active systemic bacterial, viral, fungal, or other infection at screening, including patients with suspected active or latent tuberculosis (as confirmed by a positive interferon-gamma release assay)
* History or evidence of clinically significant cardiovascular, CNS and/or other systemic disease that in the investigator's opinion would preclude participation in the study or compromise the patient's ability to give informed consent

Primary outcomes:
measure: PFS-INV
timeFrame: Time from date of randomization until Progressive Disease or death from any cause. In this trial, the primary endpoint is PFS as assessed by the investigator (up to 43 months)
Secondary outcomes:
measure: EFS-INV
timeFrame: From randomization until the first occurrence of disease progression or relapse as assessed by the INV using, start of new anti-lymphoma treatment or death from any cause, whichever occurs first (up to 43 months)
measure: OS
timeFrame: From randomization until the date of death from any cause (up to 62 months)
measure: Metabolic PET-negative CR-rate at EOT by BIRC
timeFrame: End of treatment, 4-8 weeks after last dose
measure: Metabolic PET-negative CR-rate at EOT by INV
timeFrame: End of treatment, 4-8 weeks after last dose
measure: ORR as per INV at EOT
timeFrame: 6 ± 2 weeks after End of Treatment
measure: Time to next anti-lymphoma treatment (TTNT)
timeFrame: From randomization date to start of next anti-lymphoma therapy (for any reason including disease progression, treatment toxicity, and patient preference) or death due to any cause, whatever comes first (up to 43 months)
measure: Duration of Complete Response (CR) as assessed by the investigator
timeFrame: From the date of the first occurrence of a documented CR, to the date of progression, relapse, or death from any cause, whichever is earlier (up to 43 months)
measure: EFS at 3 years
timeFrame: 36 months after randomization
measure: PFS at 3 years
timeFrame: 36 months after randomization
measure: OS at 3 years
timeFrame: 36 months after randomization
Other outcomes:
Locations:
city: Daphne
country: United States
facility: MorphoSys Research Site
state: Alabama
city: Anaheim
country: United States
facility: MorphoSys Research Site
state: California
city: Clovis
country: United States
facility: MorphoSys Research Site
state: California
city: Fullerton
country: United States
facility: MorphoSys Research Site
state: California
city: Harbor City
country: United States
facility: MorphoSys Research Site
state: California
city: Los Angeles
country: United States
facility: MorphoSys Research Site
state: California
city: San Diego
country: United States
facility: MorphoSys Research Site
state: California
city: Whittier
country: United States
facility: MorphoSys Research Site
state: California
city: Aurora
country: United States
facility: MorphoSys Research Site
state: Colorado
city: Jacksonville
country: United States
facility: MorphoSys Research Site
state: Florida
city: Honolulu
country: United States
facility: MorphoSys Research Site
state: Hawaii
city: Wichita
country: United States
facility: MorphoSys Research Site
state: Kansas
city: Lexington
country: United States
facility: MorphoSys Research Site
state: Kentucky
city: Louisville
country: United States
facility: MorphoSys Research Site
state: Kentucky
city: Baltimore
country: United States
facility: MorphoSys Research Site
state: Maryland
city: Bethesda
country: United States
facility: MorphoSys Research Site
state: Maryland
city: Columbia
country: United States
facility: MorphoSys Research Site
state: Maryland
city: Detroit
country: United States
facility: MorphoSys Research Site
state: Michigan
city: Minneapolis
country: United States
facility: MorphoSys Research Site
state: Minnesota
city: Rochester
country: United States
facility: MorphoSys Research Site
state: Minnesota
city: Kansas City
country: United States
facility: MorphoSys Research Site
state: Missouri
city: Lebanon
country: United States
facility: MorphoSys Research Site
state: New Hampshire
city: Florham Park
country: United States
facility: MorphoSys Research Site
state: New Jersey
city: Buffalo
country: United States
facility: MorphoSys Research Site
state: New York
city: Rochester
country: United States
facility: MorphoSys Research Site
state: New York
city: Canton
country: United States
facility: MorphoSys Research Site
state: Ohio
city: Cincinnati
country: United States
facility: MorphoSys Research Site
state: Ohio
city: Eugene
country: United States
facility: MorphoSys Research Site
state: Oregon
city: Danville
country: United States
facility: MorphoSys Research Site
state: Pennsylvania
city: Chattanooga
country: United States
facility: MorphoSys Research Site
state: Tennessee
city: Germantown
country: United States
facility: MorphoSys Research Site
state: Tennessee
city: Nashville
country: United States
facility: MorphoSys Research Site
state: Tennessee
city: Austin
country: United States
facility: MorphoSys Research Site
state: Texas
city: Bedford
country: United States
facility: MorphoSys Research Site
state: Texas
city: Denison
country: United States
facility: MorphoSys Research Site
state: Texas
city: Fort Worth
country: United States
facility: MorphoSys Research Site
state: Texas
city: Houston
country: United States
facility: MorphoSys Research Site
state: Texas
city: McAllen
country: United States
facility: MorphoSys Research Site
state: Texas
city: Tyler
country: United States
facility: MorphoSys Research Site
state: Texas
city: Ogden
country: United States
facility: MorphoSys Research Site
state: Utah
city: Salt Lake City
country: United States
facility: MorphoSys Research Site
state: Utah
city: Gainesville
country: United States
facility: MorphoSys Research Site
state: Virginia
city: Roanoke
country: United States
facility: MorphoSys Research Site
state: Virginia
city: Virginia Beach
country: United States
facility: MorphoSys Research Site
state: Virginia
city: Olympia
country: United States
facility: MorphoSys Research Site
state: Washington
city: Tacoma
country: United States
facility: MorphoSys Research Site
state: Washington
city: Marshfield
country: United States
facility: MorphoSys Research Site
state: Wisconsin
city: Buenos Aires
country: Argentina
facility: MorphoSys Research Site
city: Buenos Aires
country: Argentina
facility: MorphoSys Research Site
city: Cipolletti
country: Argentina
facility: MorphoSys Research Site
city: Rosario
country: Argentina
facility: MorphoSys Research Site
city: San Miguel de Tucuman
country: Argentina
facility: MorphoSys Research Site
city: Adelaide
country: Australia
facility: MorphoSys Research Site
city: Ballarat
country: Australia
facility: MorphoSys Research Site
city: Birtinya
country: Australia
facility: MorphoSys Research Site
city: Brisbane
country: Australia
facility: MorphoSys Research Site
city: Canberra
country: Australia
facility: MorphoSys Research Site
city: Clayton
country: Australia
facility: MorphoSys Research Site
city: Frankston
country: Australia
facility: MorphoSys Research Site
city: Geelong
country: Australia
facility: MorphoSys Research Site
city: Gold Coast
country: Australia
facility: MorphoSys Research Site
city: Gosford
country: Australia
facility: MorphoSys Research Site
city: Greenslopes
country: Australia
facility: MorphoSys Research Site
city: Hobart
country: Australia
facility: MorphoSys Research Site
city: Kingswood
country: Australia
facility: MorphoSys Research Site
city: Kogarah
country: Australia
facility: MorphoSys Research Site
city: Launceston
country: Australia
facility: MorphoSys Research Site
city: Malvern
country: Australia
facility: MorphoSys Research Site
city: Melbourne
country: Australia
facility: MorphoSys Research Site
city: Melbourne
country: Australia
facility: MorphoSys Research Site
city: Nedlands
country: Australia
facility: MorphoSys Research Site
city: Perth
country: Australia
facility: MorphoSys Research Site
city: Perth
country: Australia
facility: MorphoSys Research Site
city: Richmond
country: Australia
facility: MorphoSys Research Site
city: St. Albans
country: Australia
facility: MorphoSys Research Site
city: Sydney
country: Australia
facility: MorphoSys Research Site
city: Sydney
country: Australia
facility: MorphoSys Research Site
city: Townsville
country: Australia
facility: MorphoSys Research Site
city: Wahroonga
country: Australia
facility: MorphoSys Research Site
city: Waratah
country: Australia
facility: MorphoSys Research Site
city: Wollongong
country: Australia
facility: MorphoSys Research Site
city: Innsbruck
country: Austria
facility: MorphoSys Research Site
city: Linz
country: Austria
facility: MorphoSys Research Site
city: Linz
country: Austria
facility: MorphoSys Research Site
city: Rankweil
country: Austria
facility: MorphoSys Research Site
city: St. Poelten
country: Austria
facility: MorphoSys Research Site
city: Vienna
country: Austria
facility: MorphoSys Research Site
city: Vienna
country: Austria
facility: MorphoSys Research Site
city: Halifax
country: Canada
facility: MorphoSys Research Site
city: London
country: Canada
facility: MorphoSys Research Site
city: Montreal
country: Canada
facility: MorphoSys Research Site
city: Saskatoon
country: Canada
facility: MorphoSys Research Site
city: Sherbrooke
country: Canada
facility: MorphoSys Research Site
city: Medellin
country: Colombia
facility: MorphoSys Research Site
city: Valledupar
country: Colombia
facility: MorphoSys Research Site
city: Brno
country: Czechia
facility: MorphoSys Research Site
city: Hradec Králové
country: Czechia
facility: MorphoSys Research Site
city: Olomouc
country: Czechia
facility: MorphoSys Research Site
city: Ostrava
country: Czechia
facility: MorphoSys Research Site
city: Prague
country: Czechia
facility: MorphoSys Research Site
city: Prague
country: Czechia
facility: MorphoSys Research Site
city: Prague
country: Czechia
facility: MorphoSys Research Site
city: Caen
country: France
facility: Morphosys Research Site
state: Cedex 9
city: Bordeau
country: France
facility: Morphosys Research Site
state: Pessac Cedax
city: Amiens
country: France
facility: MorphoSys Research Site
city: Bordeaux
country: France
facility: MorphoSys Research Site
city: Bordeaux
country: France
facility: MorphoSys Research Site
city: La Tronche
country: France
facility: MorphoSys Research Site
city: Le Chesnay
country: France
facility: Morphosys Research Site
city: Le Mans
country: France
facility: MorphoSys Research Site
city: Lille
country: France
facility: MorphoSys Research Site
city: Limoges
country: France
facility: MorphoSys Research Site
city: Marseille
country: France
facility: MorphoSys Research Site
city: Nantes
country: France
facility: MorphoSys Research Site
city: Poitiers
country: France
facility: MorphoSys Research Site
city: Quimper
country: France
facility: MorphoSys Research Site
city: Saint-Priest-en-Jarez
country: France
facility: MorphoSys Research Site
city: Vandoeuvre-lès-Nancy
country: France
facility: MorphoSys Research Site
city: Vannes
country: France
facility: MorphoSys Research Site
city: Aachen
country: Germany
facility: MorphoSys Research Site
city: Augsburg
country: Germany
facility: MorphoSys Research Site
city: Berlin
country: Germany
facility: MorphoSys Research Site
city: Berlin
country: Germany
facility: MorphoSys Research Site
city: Berlin
country: Germany
facility: Morphosys Research Site
city: Bonn
country: Germany
facility: MorphoSys Research Site
city: Chemnitz
country: Germany
facility: MorphoSys Research Site
city: Cottbus
country: Germany
facility: MorphoSys Research Site
city: Göttingen
country: Germany
facility: MorphoSys Research Site
city: Halle
country: Germany
facility: MorphoSys Research Site
city: Heilbronn
country: Germany
facility: MorphoSys Research Site
city: Jena
country: Germany
facility: MorphoSys Research Site
city: Kassel
country: Germany
facility: MorphoSys Research Site
city: Luebeck
country: Germany
facility: MorphoSys Research Site
city: Magdeburg
country: Germany
facility: MorphoSys Research Site
city: Mainz
country: Germany
facility: MorphoSys Research Site
city: Marburg
country: Germany
facility: MorphoSys Research Site
city: Muenster
country: Germany
facility: MorphoSys Research Site
city: Munich
country: Germany
facility: MorphoSys Research Site
city: Munich
country: Germany
facility: MorphoSys Research Site
city: Paderborn
country: Germany
facility: MorphoSys Research Site
city: Tuebingen
country: Germany
facility: MorphoSys Research Site
city: Wiesbaden
country: Germany
facility: MorphoSys Research Site
city: Wuerzburg
country: Germany
facility: MorphoSys Research Site
city: Wuppertal
country: Germany
facility: MorphoSys Research Site
city: Budapest
country: Hungary
facility: MorphoSys Research Site
city: Budapest
country: Hungary
facility: MorphoSys Research Site
city: Debrecen
country: Hungary
facility: MorphoSys Research Site
city: Gyor
country: Hungary
facility: MorphoSys Research Site
city: Nyíregyháza
country: Hungary
facility: Morphosys Research Site
city: Pécs
country: Hungary
facility: MorphoSys Research Site
city: Dublin
country: Ireland
facility: MorphoSys Research Site
city: Limerick
country: Ireland
facility: MorphoSys Research Site
city: Be'er Sheva
country: Israel
facility: MorphoSys Research Site
city: Haifa
country: Israel
facility: MorphoSys Research Site
city: Jerusalem
country: Israel
facility: MorphoSys Research Site
city: Petah-Tikva
country: Israel
facility: MorphoSys Research Site
city: Ramat Gan
country: Israel
facility: Morphosys Research Site
city: Tel-Aviv
country: Israel
facility: MorphoSys Research Site
city: Bergamo
country: Italy
facility: MorphoSys Research Site
city: Brescia
country: Italy
facility: MorphoSys Research Site
city: Candiolo
country: Italy
facility: MorphoSys Research Site
city: Catania
country: Italy
facility: MorphoSys Research Site
city: Forli
country: Italy
facility: MorphoSys Research Site
city: Genoa
country: Italy
facility: MorphoSys Research Site
city: Lecce
country: Italy
facility: MorphoSys Research Site
city: Milan
country: Italy
facility: MorphoSys Research Site
city: Novara
country: Italy
facility: MorphoSys Research Site
city: Orbassano
country: Italy
facility: MorphoSys Research Site
city: Padova
country: Italy
facility: MorphoSys Research Site
city: Palermo
country: Italy
facility: MorphoSys Research Site
city: Pavia
country: Italy
facility: MorphoSys Research Site
city: Ravenna
country: Italy
facility: MorphoSys Research Site
city: Rimini
country: Italy
facility: MorphoSys Research Site
city: Rozzano
country: Italy
facility: MorphoSys Research Site
city: Siena
country: Italy
facility: MorphoSys Research Site
city: Siena
country: Italy
facility: MorphoSys Research Site
city: Terni
country: Italy
facility: MorphoSys Research Site
city: Tricase
country: Italy
facility: MorphoSys Research Site
city: Trieste
country: Italy
facility: MorphoSys Research Site
city: Turin
country: Italy
facility: MorphoSys Research Site
city: Fukuoka
country: Japan
facility: MorphoSys Research Site
city: Gifu
country: Japan
facility: MorphoSys Research Site
city: Ibaraki
country: Japan
facility: MorphoSys Research Site
city: Isehara
country: Japan
facility: MorphoSys Research Site
city: Kagoshima
country: Japan
facility: MorphoSys Research Site
city: Nagoya
country: Japan
facility: MorphoSys Research Site
city: Narita-shi
country: Japan
facility: MorphoSys Research Site
city: Okayama
country: Japan
facility: MorphoSys Research Site
city: Osakasayama-shi
country: Japan
facility: MorphoSys Research Site
city: Osaka
country: Japan
facility: MorphoSys Research Site
city: Sapporo
country: Japan
facility: MorphoSys Research Site
city: Tachikawa
country: Japan
facility: MorphoSys Research Site
city: Tokyo
country: Japan
facility: MorphoSys Research Site
city: Tokyo
country: Japan
facility: MorphoSys Research Site
city: Tokyo
country: Japan
facility: MorphoSys Research Site
city: Tsu-shi
country: Japan
facility: MorphoSys Research Site
city: Busan
country: Korea, Republic of
facility: MorphoSys Research Site
city: Busan
country: Korea, Republic of
facility: MorphoSys Research Site
city: Busan
country: Korea, Republic of
facility: MorphoSys Research Site
city: Busan
country: Korea, Republic of
facility: MorphoSys Research Site
city: Daegu
country: Korea, Republic of
facility: MorphoSys Research Site
city: Daegu
country: Korea, Republic of
facility: MorphoSys Research Site
city: Daegu
country: Korea, Republic of
facility: MorphoSys Research Site
city: Goyang-si
country: Korea, Republic of
facility: MorphoSys Research Site
city: Incheon
country: Korea, Republic of
facility: MorphoSys Research Site
city: Jeonju
country: Korea, Republic of
facility: MorphoSys Research Site
city: Jinju-si
country: Korea, Republic of
facility: MorphoSys Research Site
city: Seoul
country: Korea, Republic of
facility: MorphoSys Research Site
city: Seoul
country: Korea, Republic of
facility: MorphoSys Research Site
city: Seoul
country: Korea, Republic of
facility: MorphoSys Research Site
city: Seoul
country: Korea, Republic of
facility: MorphoSys Research Site
city: Seoul
country: Korea, Republic of
facility: MorphoSys Research Site
city: Seoul
country: Korea, Republic of
facility: MorphoSys Research Site
city: Yangsan
country: Korea, Republic of
facility: MorphoSys Research Site
city: Alor Setar
country: Malaysia
facility: MorphoSys Research Site
city: Ampang
country: Malaysia
facility: MorphoSys Research Site
city: George Town
country: Malaysia
facility: MorphoSys Research Site
city: Ipoh
country: Malaysia
facility: MorphoSys Research Site
city: Johor Bahru
country: Malaysia
facility: MorphoSys Research Site
city: Kota Bharu
country: Malaysia
facility: MorphoSys Research Site
city: Kuala Lumpur
country: Malaysia
facility: MorphoSys Research Site
city: Kuantan
country: Malaysia
facility: MorphoSys Research Site
city: Kuching
country: Malaysia
facility: MorphoSys Research Site
city: Petaling Jaya
country: Malaysia
facility: MorphoSys Research Site
city: Subang Jaya
country: Malaysia
facility: MorphoSys Research Site
city: Auckland
country: New Zealand
facility: MorphoSys Research Site
city: Manila
country: Philippines
facility: MorphoSys Research Site
city: Pasig City
country: Philippines
facility: MorphoSys Research Site
city: Quezon City
country: Philippines
facility: MorphoSys Research Site
city: Warsaw
country: Poland
facility: MorphoSys Research Site
city: Łódź
country: Poland
facility: Morphosys Research Site
city: Brasov
country: Romania
facility: MorphoSys Research Site
city: Bucharest
country: Romania
facility: MorphoSys Research Site
city: Bucharest
country: Romania
facility: Morphosys Research Site
city: Cluj-Napoca
country: Romania
facility: Morphosys Research Site
city: Craiova
country: Romania
facility: Morphosys Research Site
city: Iasi
country: Romania
facility: MorphoSys Research Site
city: Kazan
country: Russian Federation
facility: MorphoSys Research Site
city: Moscow
country: Russian Federation
facility: Morphosys Research Site
city: Novosibirsk
country: Russian Federation
facility: MorphoSys Research Site
city: Petrozavodsk
country: Russian Federation
facility: Morphosys Research Site
city: Saint Petersburg
country: Russian Federation
facility: MorphoSys Research Site
city: Saint Petersburg
country: Russian Federation
facility: MorphoSys Research Site
city: Saint Petersburg
country: Russian Federation
facility: Morphosys Research Site
city: UFA
country: Russian Federation
facility: Morphosys research site
city: Belgrade
country: Serbia
facility: MorphoSys Research Site
city: Belgrade
country: Serbia
facility: MorphoSys Research Site
city: Novi Sad
country: Serbia
facility: Morphosys Research Site
city: Sremska Kamenica
country: Serbia
facility: MorphoSys Research Site
city: Bratislava
country: Slovakia
facility: MorphoSys Research Site
city: Košice
country: Slovakia
facility: MorphoSys Research Site
city: Badalona
country: Spain
facility: MorphoSys Research Site
city: Barcelona
country: Spain
facility: MorphoSys Research Site
city: Barcelona
country: Spain
facility: MorphoSys Research Site
city: Girona
country: Spain
facility: MorphoSys Research Site
city: Jerez de la Frontera
country: Spain
facility: MorphoSys Research Site
city: Lugo
country: Spain
facility: MorphoSys Research Site
city: Madrid
country: Spain
facility: MorphoSys Research Site
city: Madrid
country: Spain
facility: MorphoSys Research Site
city: Madrid
country: Spain
facility: MorphoSys Research Site
city: Madrid
country: Spain
facility: MorphoSys Research Site
city: Madrid
country: Spain
facility: MorphoSys Research Site
city: Pamplona
country: Spain
facility: MorphoSys Research Site
city: Salamanca
country: Spain
facility: MorphoSys Research Site
city: Seville
country: Spain
facility: MorphoSys Research Site
city: Seville
country: Spain
facility: MorphoSys Research Site
city: Seville
country: Spain
facility: MorphoSys Research Site
city: Valencia
country: Spain
facility: MorphoSys Research Site
city: Vitoria-Gasteiz
country: Spain
facility: MorphoSys Research Site
city: Chang Hua
country: Taiwan
facility: Morphosys Research Site
city: Chiayi City
country: Taiwan
facility: Morphosys Research Site
city: Hualien City
country: Taiwan
facility: Morphosys Research Site
city: Kaohsiung
country: Taiwan
facility: MorphoSys Research Site
city: Kaohsiung
country: Taiwan
facility: Morphosys Research Site
city: New Taipei City
country: Taiwan
facility: Morphosys Research Site
city: Taichung
country: Taiwan
facility: Morphosys Research Site
city: Taichung
country: Taiwan
facility: MorphoSys Research Site
city: Tainan
country: Taiwan
facility: MorphoSys Research Site
city: Taipei
country: Taiwan
facility: MorphoSys Research Site
city: Taoyuan
country: Taiwan
facility: Morphsys Research Site
city: Bangkok
country: Thailand
facility: MorphoSys Research Site
city: Bangkok
country: Thailand
facility: Morphosys Research Site
city: Chiang Mai
country: Thailand
facility: Morphosys Research Site
city: Khon Kaen
country: Thailand
facility: Morphosys Research Site
city: Pathum Thani
country: Thailand
facility: MorphoSys Research Site
city: Ankara
country: Turkey
facility: MorphoSys Research Site
city: Ankara
country: Turkey
facility: MorphoSys Research Site
city: Izmir
country: Turkey
facility: MorphoSys Research Site
city: İzmit
country: Turkey
facility: MorphoSys Research Site
city: Malatya
country: Turkey
facility: MorphoSys Research Site
city: Mersin
country: Turkey
facility: MorphoSys Research Site
city: Cherkasy
country: Ukraine
facility: Morphosys Research Site
city: Chernihiv
country: Ukraine
facility: Morphosys Research Site
city: Kharkiv
country: Ukraine
facility: Morphosys Research Site
city: Kyiv
country: Ukraine
facility: Morphosys Research Site
city: Kyiv
country: Ukraine
facility: MorphoSys Research Site
city: Kyiv
country: Ukraine
facility: Morphosys Research Site
city: Aberdeen
country: United Kingdom
facility: MorphoSys Research Site
city: Bath
country: United Kingdom
facility: MorphoSys Research Site
city: Birmingham
country: United Kingdom
facility: MorphoSys Research Site
city: Bristol
country: United Kingdom
facility: MorphoSys Research Site
city: London
country: United Kingdom
facility: MorphoSys Research Site
city: London
country: United Kingdom
facility: MorphoSys Research Site
city: London
country: United Kingdom
facility: Morphosys Research Site
city: Nottingham
country: United Kingdom
facility: MorphoSys Research Site
city: Sutton
country: United Kingdom
facility: MorphoSys Research Site
city: Wolverhampton
country: United Kingdom
facility: MorphoSys Research Site
Study officials:
affiliation: Incyte Corporation
name: Incyte Medical Director
role: STUDY_DIRECTOR
References: